Introduction {#S1}
============

Diabetes mellitus (DM) is a major risk factor for ischemic and hemorrhagic stroke. Stroke patients with DM exhibit a worse neurovascular prognosis and white-matter (WM) lesion and neurological function than non-DM stroke patients. Therefore, development of therapeutic approaches for the DM-stroke population are urgently needed.

Type-2 diabetes (T2DM) constitutes 90% of the DM population. DM patients have low levels of blood high-density lipoprotein (HDL) ([@B44]; [@B64]; [@B27]; [@B7]) and impairment of HDL function such as the antioxidative capacity of HDL ([@B7]; [@B36]; [@B3]; [@B38]; [@B49]; [@B62]; [@B20]). Improved HDL functionality may contribute to maintenance of pancreas beta-cell function in subjects with well-controlled T2DM ([@B20]). Impairment of HDL anti-oxidative function in T2DM contributes to enhanced formation of oxidative stress products, such as advanced glycation end products (AGEs) ([@B49]; [@B62]). Dysfunction of HDL also promotes inflammatory effects ([@B38]) and increases proinflammatory factor activation, such as tumor necrosis factor alpha (TNFα) ([@B33]; [@B54]; [@B25]), high-mobility group box 1 (HMGB1) and AGE receptor (RAGE) ([@B74]; [@B76]), and plasminogen activator inhibitor-1 (PAI-1) ([@B61]; [@B7]; [@B74]; [@B1]; [@B76]; [@B13]; [@B26]), which can exacerbate vascular and WM damage after stroke in T2DM. Therefore, improving HDL function through modification of its lipid and/or protein content maybe a therapeutic target for the treatment of stroke in T2DM.

In human, the circulating blood contains only about 40% of the total amount of HDL, with most of HDL particles present in human interstitial fluids including the arterial intimal fluid ([@B45]). The HDL particles in plasma contain either a single copy or multiple copies of apolipoprotein A-I (ApoA-I). ApoA-I has been shown to possess several atheroprotective functions, including inhibition of inflammation. However, ApoA-I is a selective target for oxidation by myeloperoxidase, which results in impaired HDL function ([@B34]). 4F is an economical 18 amino acid peptide mimetic the tertiary structure of ApoA-I. There are two 4F species, D-4F (right hand) and L-4F (left hand). When administered subcutaneously, D-4F and L-4F are equally efficacious, D-4F is orally efficacious but L-4F is digested by gut proteases ([@B53]). Both of them have remarkable anti-inflammatory properties based on their ability to preferentially bind proinflammatory oxidized lipids and decrease serum oxidized low-density lipoprotein (LDL) level ([@B70]; [@B41]; [@B75]), improve HDL function ([@B57]; [@B70]; [@B77]; [@B53]; [@B50]; [@B60]), and increase cholesterol efflux ([@B52]; [@B66]). Our previous studies show that D-4F treatment of wild-type mice subjected to stroke reduces vascular and WM damage as well as improves recovery of neurological function 14 days after stroke ([@B15]). Rats with type-1 diabetes and subjected to stroke receiving orally administered D-4F initiated at 2 h after stroke, and subsequently at 24 and 48 h after stroke exhibit significantly decreased neuroinflammation ([@B55]). However, to our knowledge, there are no studies investigating whether L-4F has a therapeutic effect on stroke-induced vascular and WM damage in T2DM mice. In this study, we therefore investigated the hypothesis that anti-inflammation may play an important role in L-4F treatment of stroke induced neuroprotection and reduction of WM damage in a clinically relevant stroke model using db/db T2DM mice.

Materials and Methods {#S2}
=====================

Animal Stroke Model and Experimental Groups {#S2.SS1}
-------------------------------------------

The number of animals for the *in vivo* study was calculated *a priori* by power analysis. For blood biochemistry, lesion volume, and histochemical/immunohisto-staining measurement, 11 mice per group survival stroke animals were targeted to achieve a power of 0.83 at a significance level of \< 0.05, assuming 25% difference in mean, a 20% standard deviation at the 95% confidence level. For Western-blot (WB) and real time-quantitative PCR (RT-qPCR) assays, 6 stroke mice per group were needed. To meet these experimental targets, a total of 90 adult male T2DM mice (BKS.Cg-*m* + / + *Lepr^*db*^/J*, db/db mice, 3 month old, Jackson Laboratory, Wilmington, MA, United States) were used. For middle cerebral artery occlusion (MCAo) surgery, animals were anesthetized with 2% isoflorane in a jar for pre-anesthetic, and spontaneously respired with 1.5% isoflurane in 2:1 N~2~O:O~2~ mixture using a facemask connected and regulated with a modified FLUOTEC 3 Vaporizer (Fraser Harlake). Rectal temperature was maintained at 37°C throughout the surgical procedure using a feedback regulated water heating system. Transient right MCAo was induced for 1 h by advancing a 6-0 surgical nylon suture (8.0--9.0 mm), determined by the animal weight, with its tip rounded by heating near a flame, to block the origin of the MCA, using a method of intraluminal vascular occlusion modified in our laboratory ([@B42]). One hour after MCAo, reperfusion was performed by withdrawal of the suture. Two hours after suture withdrawal mice were randomly separated into three groups by drawing different colored balls:

1.  Sham-control group: mice were subjected to the same procedures as the MCAo without insertion of filament (*n* = 4 mice).

2.  MCAo group: mice were subcutaneously administered saline daily for 4 days (*n* = 52 mice).

3.  L-4F treatment group: mice were administered L-4F (BioMatik, Cambridge, ON, Canada) 16 mg/kg (*n* = 34 mice) and subsequently daily for 4 days. All survival animals were sacrificed 4 days after MCAo.

Functional Tests {#S2.SS2}
----------------

To evaluate neurological functional deficits and recovery after stroke, all animals were evaluated on the modified neurological severity score (mNSS, the total score is 12) and left foot-fault test before MCAo (as the baseline) and at 1, 3, and 4 days after MCAo, as previously described ([@B10]; [@B65]). Functional analyses were performed by an investigator blinded to the experimental groups.

Blood Biochemistry Measurement {#S2.SS3}
------------------------------

To test blood biochemistry, the animals were fasted overnight and blood was collected from tail vein before MCAo as the baseline and prior to sacrifice. Blood levels of glucose were measured using glucose test strips in a glucose analyzer (Accu-Chek Compact System; Roche Diagnostics, Basel, Switzerland), and the levels of HDL, total-cholesterol (T-CH) and triglyceride were tested using CardioChek P•A analyzer (Polymer Technology System, Inc., Indianapolis, IN, United States), following the manufacturer's instructions. Each sample was tested in triplicate and the data are presented as mg/dl values.

Cerebral Hemorrhagic Transformation, Lesion Volume, and Survival Rate Measurement {#S2.SS4}
---------------------------------------------------------------------------------

All brains were fixed by transcardial-perfusion with saline, followed by perfusion and immersion in 4% paraformaldehyde and were then embedded in paraffin. Using a mouse brain matrix (Activational Systems Inc., Warren, MI, United States), the cerebral tissues were cut into seven equally spaced (1 mm) coronal blocks, and a series of adjacent 6 μm thick sections were cut from each block. Seven coronal sections of tissue were processed and stained with hematoxylin and eosin (HE). For calculation of brain hemorrhage volume, the percentage areas of petechial and gross hemorrhage were measured in each histological section and summed. For lesion volume measurement, the indirect lesion area was calculated, in which the intact area of the ipsilateral hemisphere was subtracted from the area of the contralateral hemisphere. Lesion volume is presented as a volume percentage of the lesion compared with the contralateral hemisphere ([@B68]). For evaluation of mortality, all animals were counted daily. The total number of dead animals in each group was counted within the 4 days after MCAo. The survival rate is presented as a percentage of the total number of stroke animals in each group.

Histochemical and Immuno-Staining {#S2.SS5}
---------------------------------

For histochemical/immunostaining, a standard paraffin block was obtained from the center of the lesion (bregma −1 to +1 mm). A series of 6-μm thick sections were cut from the block. Every 10^*th*^ coronal section for a total of five sections was used. Histochemical-staining for Bielshowsky silver (BS, an axon marker) and Luxol fast blue (LFB, a myelin marker), or histoimmino-staining for antibodies against albumin (BBB leakage marker, 1:500; Abcam), von Willebrand Factor (vWF, a vessel marker, 1:400; Dako), α-smooth muscle actin (αSMA, a smooth muscle cell-SMC marker, 1:800, Dako), SMI31 (a marker of phosphorylated-neurofilament, 1:1000, Covance), platelet-derived growth factor receptor alpha (PDGFRα, a marker of oligodendrocyte progenitor cells-OPCs, 1:100, Chemicon), and HMGB1 (1:800, Abcam) were performed. For immunostaining measurement, five sections with each section containing 8 fields of view within the cortex and striatum from the ischemic boundary zone (IBZ), defined as the area surrounding the lesion, which morphologically differs from the surrounding normal tissue, were digitized using a 40X objective (Olympus BX40) using a 3-CCD color video camera (Sony DXC-970MD) interfaced with an MCID computer imaging analysis system (Imaging Research, St. Catharines, ON, Canada).

BBB Leakage Measurement {#S2.SS6}
-----------------------

Cerebral infiltration of albuminuria, which is associated with DM, has been flagged as a predictor for cerebrovascular events ([@B2]) and as an index of BBB permeability ([@B72]). In this study, to test whether L-4F treatment enhances BBB-integrity after stroke in T2DM mice, the albumin density in the ischemic brain was measured. The positive area of albumin in the ischemic border area is presented.

Vascular Density, Perimeter/Diameter, and Cell Number Measurement {#S2.SS7}
-----------------------------------------------------------------

vWF-immunoreactivity was employed to identify vascular vessels, and αSMA was used as a marker of arterioles ([@B30]). The density and perimeter of vWF-coated vessels, and the number and diameter of αSMA-positive arterioles (have only one to two layers of SMCs, diameter 10--20 μm) were analyzed in the IBZ. The diameter is presented as the average of a total 10 largest arteries in the IBZ.

WM Density and OPC Number Measurement {#S2.SS8}
-------------------------------------

For measurement of WM-density, the BS, LFB, or SMI31 -positive area in the WM bundles of striatum and the total number of PDGFRα^+^-OPCs in the IBZ of the striatum were measured in each referenced coronal section using the MCID computer imaging analysis system.

Real-Time RT-PCR Assay {#S2.SS9}
----------------------

Tissues from the ischemic area of the ipsilateral hemisphere from both vehicle-control and L-4F-treatment T2DM mice were isolated 4 days after MCAo. Total RNA was isolated using a standard protocol. Quantitative PCR was performed on an ABI 7000 PCR instrument (Applied Biosystems, Foster City, CA, United States) using three-stage program parameters provided by the manufacturer. Each sample was tested in triplicate, and analysis of relative gene expression data using the 2^--ΔΔ*CT*^ method. The following primers for RT-PCR were designed using Primer Express software (ABI). TNFα: Fwd: TACTCCCAGGTTCTCTTCAAGG, Rev: GAGGTTGACTTTCTCCTGGTA; PAI-1: Fwd: GTCTTTCCG ACCAAGAGCAG.

Rev: ATCACTTGGCCCATGAAGAG; GAPDH: Fwd: AGA ACA TCA TCC CTG CAT CC, Rev: CAC ATT GGG GGT AGG AAC AC.

Western Blot (WB) Assay {#S2.SS10}
-----------------------

Equal amounts of brain-tissue lysate from the ischemic area of the ipsilateral hemisphere were subjected to WB analysis. Specific proteins were visualized using a SuperSignal West Pico chemiluminescence kit (Pierce). The following primary antibodies were used: anti-RAGE (1:1000, rat, R&D MAB1179), anti-HMGB1 (1:1000, rabbit, Abcam ab18256), anti-TNFα (1: 1000, Abcam ab9755), anti-PAI-1 (1:500, rabbit, Santa Cruz sc-8979), anti-ED1 (CD68, 1:800, Bio-rad, MCA341, a single chain glycoprotein of 90--110 kDa, is the widely used pan-macrophage marker), and anti-β-actin (1:2000; Santa Cruz sc-1616) for 16 h at 4°C. The membranes were washed with blocking buffer without milk, and then incubated with horseradish peroxidase-conjugated secondary antibody in blocking buffer.

Mouse Brain Cerebral Endothelial Cell (bEnd.3) Culture and Capillary-Like Tube Formation Assay {#S2.SS11}
----------------------------------------------------------------------------------------------

The bEnd.3 cell line (ATCC, cat\# CRL02299) was used. Briefly, 0.1 ml growth factor reduced Matrigel (Becton Dickinson) was added per well of a 96 well plate, and cells (2 × 10^4^ cells) were seeded in Matrigel and cultured with serum free DMEM medium. The cells were divided into four groups (*n* = 6 wells/group), and treated with: (1) normal-glucose (12.5 mM glucose) as control; (2) high-glucose (HG, 37.5 mM glucose); (3) HG + L-4F (50 ng/ml); (4) HG + L-4F (100 ng/ml). Cells were incubated for 5 h and the capillary tube formation measurement was performed. For quantitative measurements of capillary tube formation, Matrigel wells were digitized under a 4X objective (Olympus BX40). Tracks of cells organized into networks of cellular cords (tubes) were counted and averaged in randomly selected three microscopic fields, and the total tube length of capillary tube formation was measured using a video camera (Sony DXC-970MD) interfaced with the MCID image analysis system.

Primary Artery Cell Migration Measurement {#S2.SS12}
-----------------------------------------

To investigate whether L-4F treatment promotes arterial cell migration in hyperglyceridemia, a primary artery explant culture model was employed ([@B16]). The aorta was surgically removed from adult C57BL/6 wild-type mice (6--8 weeks, purchased from Jaxson Lab) 24 h after MCAo. The artery explant was cut to 1 mm^3^ and placed in Matrigel and cultured with DMEM medium containing 2% B27. The artery explants were divided into four groups as follows: (1) normal glucose (12.5 mM) as a control; (2) HG (37.5 mM glucose); (3) HG + L-4F (50 ng/ml); (4) HG + L-4F (100 ng/ml). Arterial explant cultures were allowed to grow for 5 days before being photographed and the 10 longest distances of outgrowth were measured under a microscope at 4X magnification, processed with the MCID and averaged. *n* = 6/group.

Primary Cortical Neuron (PCN) Culture and Neurite/Axonal Outgrowth Measurements {#S2.SS13}
-------------------------------------------------------------------------------

The PCNs derived from E15 C57BL/6 embryos were employed, as previously described ([@B15]). Briefly, embryos were removed, and the cerebral cortex was dissected out, stripped of meninges, and dissociated by a combination of Ca^2+^- and Mg^2+^- free Hanks balance salt solution (HBSS) containing 0.125% trypsin digestion and mechanical trituration. The dissociated cell suspensions were seeded into poly-[L]{.smallcaps}-lysine precoated plates in a density of 10^5^ cells/cm^2^. The cells were grown in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen, Carlsbad, CA, United States) supplemented with 5% fetal bovine serum (FBS, GIBCO, Grand Island, NY, United States) at 37°C with 5% CO~2~. After 24 h, the cell cultures were switched to incubate with serum-free neurobasal medium (Invitrogen) with 2% B27 supplement (GIBCO), 0.5 mM [L]{.smallcaps}-glutamine, and 1% antibiotic- antimycotic media.

To test whether L-4F dose-dependently increases neurite-outgrowth in hyperglycemia after ischemia, the PCN cultures were subjected to 2 h of oxygen and glucose deprivation (OGD) on day-*in vitro* 4 (DIV4) followed by 24 h of reperfusion. The DIV5 OGD-PCNs were randomly divided into (*n* = 6 wells/group): (1) normal glucose control; (2) HG; (3) + L-4F 50 ng/ml; (4) + L-4F 100 ng/ml for 24 h. The PCN cultures were then stained with TUJ1 (a phenotypic marker of neural cells, 1:1000, Covance) with Cy3 and photographed using a 10 × objective fluorescent microscope (Zeiss). The average length of the 20 longest neurites in each well was calculated ([@B15]).

For testing whether L-4F increases axonal-outgrowth in HG condition, the axonal-outgrowth was measured using a microfluidic axonal growth model (Standard Neuron Device; catalog No SND450, Xona Microfluidics) ([@B15]). On DIV4, the PCN cultures were divided into four groups (*n* = 6 well/group): (1) normal glucose control; (2) HG; (3) + L-4F 50 ng/ml; (4) + L-4F 100 ng/ml. All axon-cultures were allowed to grow for an additional 48 h and were subjected to TUJ-1 immunostaining, and the axonal-outgrowth was measured on DIV6. The average length of the 10 longest axons in each well was calculated.

Statistical Analysis {#S2.SS14}
--------------------

One-way ANOVA followed by Tukey *Post Hoc* Test were used for analysis of the differences among the three or four groups of sham, MCAo and L-4F treatment *in vivo* or *in vitro* experiments. *p* \< 0.05 was set as a significant difference, and all data are presented as mean ± Standard Error (SE).

Results {#S3}
=======

L-4F-Treatment Deceases Hemorrhage/Lesion Volume and Mortality Rate, and Improves Functional Outcome After Stroke in T2DM Mice {#S3.SS1}
------------------------------------------------------------------------------------------------------------------------------

There were no significant differences in the levels of blood glucose, HDL, T-CH, and triglyceride among animals of sham-control (*n* = 4) and MCAo groups treated with or without L-4F (*n* = 11/group) 4 days after MCAo, respectively ([Figures 1A,B](#F1){ref-type="fig"}). However, L-4F treatment of MCAo mice significantly decreased hemorrhage volume ([Figure 1C](#F1){ref-type="fig"}, *n* = 11/group), and reduced lesion volume ([Figure 1D](#F1){ref-type="fig"}, *n* = 11/group) and mortality rate ([Figure 1E](#F1){ref-type="fig"}, *n* = 52 in MCAo-control group, *n* = 34 in L-4F treatment group) compared to the MCAo-control group (*p* \< 0.05).

![L-4F treatment did not change blood biochemistry, but decreases hemorrhage/lesion volumes in the ischemic brain and reduces mortality, and improves functional outcome in T2DM mice 4 days after MCAo. **(A)** Blood levels of glucose; **(B)** blood level of HDL, T-CH, and triglyceride; **(C)** hemorrhage volume; **(D)** lesion volumes; **(E)** survival rate; **(F,G)** functional outcome.](fnins-13-01127-g001){#F1}

Stroke induced significant functional deficits as indicated by significantly increased mNSS and left foot-fault at 1, 3, and 4 days in T2DM mice in the MCAo-control group (*n* = 11) compared with non-stroke T2DM mice in the sham-control group (*n* = 4, *p* \< 0.05). L-4F treatment significantly improved neurological functional outcome 4 days after MCAo in T2DM-stroke mice ([Figures 1F,G](#F1){ref-type="fig"}, *p* \< 0.05, *n* = 11/group). These data indicate that L-4F significantly decreases cerebral hemorrhagic transformation and reduces lesion volume and mortality as well as improves neurological functional outcome, independently of blood HDL and glucose level.

L-4F Treatment Reduces Vascular Damage in the Ischemic Brain in T2DM Mice {#S3.SS2}
-------------------------------------------------------------------------

There was no albumin infiltration in the non-stroke brains (*n* = 4). However, albumin infiltration was observed in the ischemic core area in the T2DM-stroke brains, and the albumin density was significantly decreased in the L-4F treatment group compared with MCAo-control group ([Figure 2A](#F2){ref-type="fig"}, *p* \< 0.05, *n* = 11/group). These data indicate that the integrity of the BBB was compromised in the ischemic brain in T2DM stroke mice, and early L-4F treatment protects BBB integrity in the ischemic brain after stroke in T2DM mice. These data (i.e., BBB disruption as measured using albumin) are consistent with our previous study that D-4F enhances BBB-integrity as detected by Evans blue (EB) dye infiltration detection in the ischemic brain in C57BL/6 wild type mice after stroke ([@B15]).

![L-4F treatment decreases BBB-leakage, increases SMC number and arteriolar diameter in the ischemic brain in T2DM mice 4 days after MCAo; **(A)** albumin-immunostaining and quantitative data; **(B)** αSMA-immunostaining and quantitative data. **(C)** Numbers of αSMA^+^-cells in the arteriolar walls. Scale bar = 25 μm; *n* = 4 in sham-control group, *n* = 11 in MCAo-control and L-4F treatment group.](fnins-13-01127-g002){#F2}

Using vascular density, diameter and perimeter to indicate vascular structure changes, we found that there is no difference in the density/perimeter of vWF^+^-vessels among the sham-control, MCAo-control and L-4F treatment groups, and no differences in the density of αSMA^+^-arterioles between sham-control and MCAo-control groups. However, both the diameter of αSMA^+^-arterioles and the number of αSMA^+^-SMCs were significantly decreased in the MCAo-control group (*n* = 11) compared with sham-control group (*n* = 4), and the diameter of αSMA^+^-arterioles ([Figure 2B](#F2){ref-type="fig"}) and the number of αSMA^+^-SMCs ([Figure 2C](#F2){ref-type="fig"}) in the IBZ significantly increased in the L-4F treatment group compared with MCAo-control group (*p* \< 0.05, *n* = 11/group). These data indicate that vascular structure was damaged in ischemic brain in T2DM stroke mice, and early L-4F treatment has a vascular protective effect on the ischemic brain after stroke in T2DM mice.

L-4F Treatment Decreases WM-Damage and OPC Loss in the Ischemic Brain in T2DM Mice {#S3.SS3}
----------------------------------------------------------------------------------

To investigate whether L-4F reduces WM-damage and OPC loss after stroke, we measured the densities of BS^+^ (axon marker, [Figure 3A](#F3){ref-type="fig"}), αSMI31^+^ (phosphorylated-neurofilament marker, [Figure 3B](#F3){ref-type="fig"}), LFB^+^ (myelin marker, [Figure 3C](#F3){ref-type="fig"}) and the number of PDGFR(+-OPCs ([Figure 3D](#F3){ref-type="fig"}) in the IBZ of striatum in the ischemic ipsilateral hemisphere, respectively. Compared with sham-control mice (*n* = 4), the MCAo-control mice (*n* = 11) exhibited a significant decrease in the densities of axons, phosphorylated-neurofilament, myelin and the number of OPCs 4 days after MCAo (*p* \< 0.05). However, L-4F treatment significantly increased the densities of axons, phosphorylated-neurofilaments, myelin and the number of OPCs 4 days after MCAo compared with MCAo-control group (*p* \< 0.05, *n* = 11/group). These data indicate that L-4F treatment decreases WM damage and OPC loss after stroke in T2DM mice.

![L-4F treatment increases WM density and OPC numbers in the ischemic brain in T2DM mice 4 days after stroke. **(A)** BS^+^ -axon and quantitative data; **(B)** SMI31^+^ -neurofilament and quantitative data; **(C)** LFB^+^ -myelin and quantitative data; **(D)** PDGFRα^+^ -OPCs and quantitative data. Scale bar in **(A,C)** = 40 μm; in **(B,D)** = 20 μm. ^∗^*p* \< 0.05, *n* = 4 in sham-control group, *n* = 11 in MCAo-control and L-4F treatment group.](fnins-13-01127-g003){#F3}

L-4F Treatment Reduces Macrophage Infiltration and Decreases RAGE/HMGB1 and PAI-1 Expression in the Ischemic Brain After Stroke in T2DM Mice {#S3.SS4}
--------------------------------------------------------------------------------------------------------------------------------------------

To investigate the mechanism underlying L-4F treatment-induced neuroprotection in T2DM, the macrophage infiltration was measured by ED1 protein level, and the protein and mRNA levels of HMGB1, RAGE, TNFα, and PAI-1 were measured by using immunostaining, WB or RT-PCR assay, respectively. The data show that L-4F treatment significantly decreases HMGB1 protein levels measured by immunostaining ([Figures 4A--D](#F4){ref-type="fig"}, *n* = 11/group) and reduces RAGE/ED/HMGB1 level measured by WB ([Figures 4E,F](#F4){ref-type="fig"}, *n* = 6/group). Moreover, L-4F treatment significantly decreases TNFα and PAI-1 protein and mRNA level ([Figures 4G--I](#F4){ref-type="fig"}) in the ischemic ipsilateral brain compared to MCAo-control group (*p* \< 0.05, *n* = 6/group).

![L-4F treatment decreases RAGE/ED1/HMGB-1, and PAI-1 in the ischemic brain in T2DM mice 4 days after MCAo. **(A--D)** HMGB-1 immunostaining and quantitative data; **(E,F)** RAGE/ED1/HMGB-1 WB assay and quantitative data; **(G,H)** TNFα/PAI-1 WB assay and quantitative data; **(I)** TNFα/PAI-1 RT-PCR data. Scale bar in **(A--C)** = 50 μm; ^∗^*p* \< 0.05, *n* = 11/group in **(A--D)**; *n* = 6/group in **(A--I)**.](fnins-13-01127-g004){#F4}

L-4F Treatment Does Not Change Capillary-Like Tube Formation, but Increases Artery Explant Cell Migration Under HG Condition {#S3.SS5}
----------------------------------------------------------------------------------------------------------------------------

To confirm the *in vivo* findings, *in vitro* capillary-like tube formation assay for angiogenesis and primary artery explant cell migration for artery function test were employed. L-4F treatment at concentrations of 50 or 100 ng/ml did not increase capillary tube formation under HG conditions compared to non-treatment control ([Figure 5A](#F5){ref-type="fig"}). However, L-4F treatment significantly increases artery explant cell migration at both 50 and 100 ng/ml concentration in HG media ([Figure 5B](#F5){ref-type="fig"}, *p* \< 0.05, *n* = 6/group) compared to non-treatment control, respectively. These data suggest that L-4F does not change angiogenesis, but increases arterial function in HG condition.

![L-4F treatment does not change capillary-like tube formation, but increases artery cell migration in normal and HG condition. **(A)** *In vitro* capillary-like tube formation and quantitative data; **(B)** primary cultured artery cell migration and quantitative data in normal and high glucose condition. ^∗^*p* \< 0.05, *n* = 6 well/group.](fnins-13-01127-g005){#F5}

L-4F Treatment Increases Neurite/Axonal Outgrowth in HG Condition {#S3.SS6}
-----------------------------------------------------------------

To confirm the *in vivo* findings that L-4F treatment protects WM damage, we measured the neurite and axonal outgrowth under HG conditions. To mimic *in vivo* ischemia, the PCNs were subjected to 2 h of OGD. The data show that HG decreases PCN neurite outgrowth, but L-4F treatment (both 50 and 100 ng/ml) significantly increases PCN neurite outgrowth after ischemia ([Figure 6A](#F6){ref-type="fig"}). In addition, L-4F (50 and 100 ng/ml) also increases and axonal outgrowth in HG condition compared with non-treatment control group ([Figure 6B](#F6){ref-type="fig"}, *p* \< 0.05, *n* = 6 wells/group).

![L-4F treatment increases neurite and axonal outgrowth under HG condition. **(A)** *In vitro* neurite outgrowth and quantitative data. **(B)** Axonal-outgrowth and quantitative data. ^∗^*p* \< 0.05, *n* = 6 well/group.](fnins-13-01127-g006){#F6}

Discussion {#S4}
==========

T2DM confers increased micro- and macro- vascular complications and amplifies of morbidity and mortality after ischemic stroke ([@B4]; [@B43]). Compared to non-DM stroke patients, T2DM stroke patients have chronic states of oxidative stress and inflammation, which accompany long-term endothelial dysfunction and impaired vasodilation, and increased vasogenic edema, BBB damage, and secondary hemorrhage transformation ([@B8]; [@B37]; [@B22]; [@B58]; [@B18]). WM-damage is an important prognostic factor for the development of functional deficits after stroke ([@B2]), BBB and WM damage which are associated with enlarged infarct volume and worse functional outcome after stroke is found in both the experimental T2DM rodents and T2DM patients ([@B47]; [@B21]; [@B3]). D-4F increases arterial concentrations of hemeoxygenase-1 and superoxide dismutase, decreases superoxide levels and endothelial cell fragmentation, and restores arterial vasoreactivity to normal in DM animal models ([@B56], [@B57]; [@B37]; [@B66]). In a mouse model of systemic sclerosis, D-4F functioned to improve vasodilation and angiogenic potential, while reducing myocardial inflammation and oxidative stress ([@B66]). In addition, L-4F dramatically improves impaired vasodilation in LDL receptor knockout (Ldlr−/−) mice, via decreased oxidative damage to endothelium ([@B56]). In our previous study, using a dose-dependent effect on MCAo model in wild type mice, an elevated concentration of D-4F (32 mg/kg) did not provide increased benefit on neurovascular and WM remodeling compared to treatment with a reduced concentration (16 mg/kg) ([@B15]). D-4F and L-4F have similar anti-inflammatory properties ([@B70]; [@B41]; [@B75]). Therefore, in the present study, the dose of 16 mg/kg L-4F, the same as the optimal dose of D-4F identified from our previous study was used. db/db mice are gene knockout mice which mimic features of human T2DM and have been widely used to investigate diabetic stroke ([@B71]; [@B40]; [@B9]; [@B16]; [@B39]; [@B67]). The db/db stroke mice exhibit increased neurovascular and WM damage and hemorrhagic/mortality rate compared with non-DM stroke mice ([@B9]; [@B16]; [@B76]). In the current study, db/db mice were employed as the T2DM model. We found that L-4F treatment initiated from 2 h post-stroke onset significantly decreased animal mortality rate and hemorrhage/infarct volume, decreased BBB leakage and WM damage, as well as increased vascular SMC and OPC numbers and enlarged arteriolar diameter in the ischemic brain 4 days after stroke. *In vitro* study shows that L-4F treatment did not change angiogenesis of mouse cerebral endothelial cells, but increased artery explant cell migration and neurite/axon outgrowth under HG condition. These data suggest that improving vascular integrity and retaining vasodilation as well as protecting WM damage, but not necessarily angiogenesis may play important role in L-4F induced neuroprotective effects.

In the brain of both T2DM patients and animal models, the extensive vascular and WM damage are highly associated with and are a consequence of inflammation ([@B24]; [@B74]; [@B3]; [@B19]). Under normal physiology, RAGE is expressed at low levels, but it is highly upregulated in T2DM under chronic inflammation states because of the accumulation of various RAGE ligands such as AGEs and HMGB1. Blocking RAGE signaling in cell and animal models has revealed that targeting RAGE impairs inflammation and progression of DM vascular complications ([@B32]). M1-phage macrophages (ED1^+^) constitute about 70% of infiltrating cells and exert a major inflammatory function in the brain lesions ([@B69]). HMGB1 is mainly released from activated immune cells, such as the peripherally infiltrating immune cells (e.g., macrophage/monocytes) in the ischemic brain ([@B73]; [@B59]; [@B14]). HMGB-1 functions also as a proinflammatory factor, promotes cell toxicity and cell death, regulates clot-promoting properties which propagate further inflammation and coagulation ([@B63]), and contributes to the initiation and progression of stroke ([@B31]). In the present study, L-4F treatment significantly reduced macrophage infiltration and HMGB1/RAGE level. These data suggest that L-4F treatment suppresses neuroinflammation in the ischemic brain, which may contribute to L-4F induced neuroprotective effects in T2DM stroke mice.

High stroke risk in T2DM patients is often related to their accelerated endothelial dysfunction which is accompanied by an array of abnormalities, including altered endothelial-dependent vasodilation, and an imbalance between local pro- and anticlotting factors ([@B61]; [@B7]; [@B1]; [@B13]; [@B26]). The AGE/RAGE signaling pathway not only promotes inflammation such as TNFα and cell death, but also increases endothelial activation biomarker PAI-1 expression in cultured endothelial cells ([@B29]; [@B28]). Moreover, TNFα also exerted a stimulatory effect on PAI-1 protein release and increased PAI-1 mRNA levels in T2DM ([@B5]; [@B17]). Recombinant human HMGB1 increases the secretion of PAI-1 and tissue plasminogen activator (tPA) in cultured human endothelial cells, and elicits proinflammatory responses of endothelial cells and may contribute to alterations in endothelial cell function in human inflammation ([@B23]). HMGB-1 can bind to both tPA and plasminogen, and enhance tPA-dependent fibrinolytic activity, while PAI-1 is a key negative regulator of fibrinolysis through inhibition of plasminogen and tPA ([@B61]; [@B7]; [@B1]; [@B13]; [@B26]). Moreover, PAI-1 exerts various cellular effects independently of fibrinolysis, such as insulin resistance, metabolic abnormalities and endothelial dysfunction as well as pro-inflammatory effects ([@B12]; [@B35]). PAI-1 is significantly increased in DM subjects compared with non-DM subjects with or without cardiovascular disease ([@B61]; [@B7]; [@B1]; [@B13]; [@B26]). In the present study, L-4F treatment significantly decreases TNFα and PAI-1 expression in the ischemic brain which may partially contribute to L-4F treatment-induced vascular and WM protection in T2DM stroke mice.

Plasma levels of HDL and glucose are highly associated with WM lesions in T2DM patients not receiving insulin treatment ([@B3]). Moreover, severe vascular and WM damage and neurological functional deficits in diabetic stroke populations are highly associated with dysfunction of HDL in the plasma ([@B3]; [@B38]). Using ApoE-null (ApoE-/-) mice, administration of L-4F (20 mg/kg body weight, once daily subcutaneously) increases HDL level and ApoA-I concentration at 72 h post initial dosing ([@B11]). However in our study, T2DM mice subjected to stroke and treated with L-4F for 4 days did not exhibit significant changes in blood HDL cholesterol, triglyceride and glucose levels. Our data are consistent with others that D-4F or L-4F have no effect on blood T-CH or HDL concentrations ([@B52], [@B51], [@B53]; [@B37]; [@B57]; [@B6]; [@B70]; [@B77]; [@B48]; [@B66]; [@B50]). Other studies show that D-4F or L-4F reduces proinflammatory HDL levels and changes HDL function, increases cholesterol efflux, reduces lipoprotein oxidation and improves arterial vasoreactivity in T2DM patients, and in DM mice and rats ([@B52], [@B51], [@B53]; [@B37]; [@B57]; [@B6]; [@B70]; [@B77]; [@B48]; [@B66]; [@B50]). In addition, high levels of blood PAI-1 are associated with decreased functional HDL in T2DM patients ([@B7]; [@B1]; [@B26]). HDL can also regulate inflammatory responses in various types of cells that have been activated by proinflammatory stimuli in the arterial wall cells including endothelial cells and vascular SMCs ([@B46]). Therefore, we speculate that L-4F treatment may improve HDL function and decrease neuroinflammation, and thereby lessens vascular and WM damage after stroke in db/db T2DM mice.

Conclusion {#S5}
==========

This study demonstrates that L-4F, an economical ApoA-I mimetic peptide, reduces neurovascular and WM damage via reducing proinflmammatory factors RAGE/HMGB-1 and TNFα/PAI-1 in the ischemic brain in db/db T2DM stroke mice. These provide a proof-of-concept that treatment with L-4F is a potential strategy to reduce neuroinflammation in the T2DM stroke population.
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